CLINICAL AND FUNCTIONAL COURSE OF COPD IN HYPERTENSIVE PATIENTS WITH CONCOMITANT CHRONIC-BRONCHITIS AND EMPHYSEMA DURING TREATMENT WITH AN ACE INHIBITOR, PERINDOPRIL
A. Overlack et al., CLINICAL AND FUNCTIONAL COURSE OF COPD IN HYPERTENSIVE PATIENTS WITH CONCOMITANT CHRONIC-BRONCHITIS AND EMPHYSEMA DURING TREATMENT WITH AN ACE INHIBITOR, PERINDOPRIL, Journal of drug development, 6(1), 1993, pp. 5-9
To assess the safety of angiotensin converting enzyme (ACE) inhibition
in chronic obstructive pulmonary disease (COPD), 60 patients with ess
ential hypertension and COPD were treated with perindopril or placebo
for six weeks in a randomised, double-blind study. Forced expiratory v
olume in the first second, peak expiratory flow rate and clinical seve
rity of COPD were not significantly different between the perindopril
and placebo groups. The number of unwanted side effects and withdrawal
s was similar in both groups and none of the patients on perindropril
exhibited significant clinical or functional impairment of COPD. ACE i
nhibitor-induced cough occurred in one out of 34 patients on perindopr
il (2.9%). It is concluded from these results that ACE inhibition is a
safe therapeutic option for patients with hypertension and concomitan
t chronic obstructive airways disease.